Table 3.
Characteristics at the time for the examination in 2010 (first recruitment phase) respectively 2012/2013 (second recruitment phase) of the participants in groups Ap – Dp.
| Ap (N = 12) | Bp (N = 10) | Cp (N = 15) | Dp (N = 15) | |
|---|---|---|---|---|
| Age, mean (SD) | 61 (6) | 67 (6) | 64 (7) | 63 (8) |
| BMI, mean (SD) | 26.4 (3.9) | 25.6 (2.8) | 26.4 (2.1) | 28.2 (4.4) |
| Sex; female/male | 2/10 | 4/6 | 8/7 | 4/11 |
| Current smoker/ex-smoker | 9/3 | 3/7 | 4/11 | 0/0 |
| FEV1/VCa, mean (SD) | 0.50 (0.11) | 0.54 (0.08) | 0.76 (0.02) | 0.78 (0.04) |
| FEV1% predicteda, mean (SD) | 65.8 (14.1) | 65.4 (12.0) | 107.3 (13.9) | 106.6 (14.6) |
| Range | 33.0–78.4 | 45.5–79.2 | 86.4–135.2 | 84.3–136.7 |
| FEV1 decline ml/year, mean (SD) | −87.3 (25.2) | −10.1 (20.3) | −1.0 (11.2) | −5.3 (14.0) |
| Physician-diagnosed COPD | 5 (41.7) | 8 (80.0) | 0 | 0 |
| Productive cough, n (%) | 3 (25.0) | 4 (40.0) | 2 (13.3) | 1 (6.7) |
| mMRC ≥ 2, n (%) | 2 (16.7) | 4 (44.4)d | 0d | 0 |
| Exacerbation mildb, n (%) | 1 (8.3) | 2 [20] | 0 | 0 |
| Exacerbation moderatec, n (%) | 0 | 2 (20.0) e | 1 (6.7) f | 0 |
| Heart diseaseg, n (%) | 3 (25.0) | 3 (30.0) | 3 (20.0) | 2 (13.3) |
| Diabetes, n (%) | 2 (16.7) | 2 (20.0) | 1 (6.7) | 1 (6.7) |
aBased on values best of pre- and post-bronchodilation.
bIncreased medication or received new medication during the last 12 months.
cTreatmed with antibiotics and/or oral steroids during the last 12 months.
dOne person in each of the groups B and C was excluded due to impaired mobility for reasons other than respiratory.
eTwo persons were treated, one of them was treated twice.
fAntibiotics.
gHeart disease include any of angina pectoris, percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), myocardial infarction, or chronic heart failure.